Product approval information indicated for:
◦Control and prevention of bleeding episodes in adults and children (0-16 16 years) with Hemophilia A.
◦Perioperative management in adults and children (0-16 years) with 18 Hemophilia A.
◦Routine prophylaxis to prevent or reduce the frequency of bleeding 20 episodes in adults and children (0-16 years) with Hemophilia A.
•Advate is not indicated for the treatment of von Willebrand disease.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/bSs0RF4
No comments:
Post a Comment